Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered into a definitive Agreement and Plan of Merger to acquire Monogram Technologies Inc. On 11 July 2025 the company and its wholly-owned subsidiary, Honey Badger Merger Sub, signed the merger agreement under which Merger Sub will be merged into Monogram, making Monogram a wholly-owned subsidiary of Zimmer Biomet at closing.
Transaction consideration will be paid entirely in cash plus a contractual contingent value right (CVR):
- Monogram common stockholders will receive $4.04 per share in cash plus one CVR.
- Series D preferred holders will receive $2.25 per share in cash plus any accrued but unpaid dividends.
- Series E preferred holders will receive $100.00 per share in cash.
The company furnished an investor presentation (Exhibit 99.1) and a joint press release (Exhibit 99.2); both are incorporated by reference but are deemed “furnished,” not “filed,” under the Exchange Act. Zimmer Biomet stresses that forward-looking statements in the materials are subject to numerous risks, including regulatory approvals, Monogram shareholder approval, competing offers, integration challenges, and potential termination fees.
No financial statements or pro-forma financial data were included in this Form 8-K. Closing timing and expected financial impact were not disclosed.